{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=H3+K27M&page=2",
    "query": {
      "condition": "H3 K27M",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=H3+K27M&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T16:10:34.805Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05762419",
      "title": "FUS Etoposide for DMG",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant"
      ],
      "interventions": [
        {
          "name": "Etoposide; Oral, 50 Mg",
          "type": "DRUG"
        },
        {
          "name": "Focused ultrasound with neuro-navigator-controlled sonication",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "4 Years to 21 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-06-05",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05762419"
    },
    {
      "nct_id": "NCT05518838",
      "title": "Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "OKN-007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oblato, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "13 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "13 Months to 18 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-11-08",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05518838"
    },
    {
      "nct_id": "NCT03134131",
      "title": "Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "ONC201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03134131"
    },
    {
      "nct_id": "NCT04943848",
      "title": "rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant"
      ],
      "interventions": [
        {
          "name": "rHSC-DIPGVax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Balstilimab",
          "type": "DRUG"
        },
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Months to 18 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-01-10",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 3,
      "location_summary": "Orange, California • Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04943848"
    },
    {
      "nct_id": "NCT07389278",
      "title": "Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "High-Grade Glioma (WHO III-IV)",
        "High-grade Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Diffuse Hemispheric Glioma, H3G34 Mutant"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20 (Arginine deiminase pegylated)",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Radiation Therapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sabine Mueller, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 97,
      "start_date": "2026-03-09",
      "completion_date": "2035-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07389278"
    },
    {
      "nct_id": "NCT05580562",
      "title": "ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "H3 K27M",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Dordaviprone (ONC201)",
          "type": "DRUG"
        },
        {
          "name": "Dordaviprone (ONC201) + Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 510,
      "start_date": "2023-01-23",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05580562"
    },
    {
      "nct_id": "NCT05500508",
      "title": "Oral AMXT 1501 Dicaprate in Combination With IV DFMO",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Solid Carcinoma",
        "Advanced Cancer",
        "DIPG Brain Tumor",
        "Ovary Cancer",
        "Breast Cancer",
        "Papillary Thyroid Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Nsclc",
        "Mesotheliomas Pleural",
        "Mesothelioma Peritoneum",
        "Esophageal Cancer",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Melanoma",
        "Colorectal Cancer",
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "AMXT1501",
          "type": "DRUG"
        },
        {
          "name": "DFMO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aminex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-11-29",
      "completion_date": "2024-12-12",
      "has_results": false,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500508"
    },
    {
      "nct_id": "NCT04541082",
      "title": "Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Nervous System Neoplasms",
        "Glioblastoma",
        "Gliosarcoma, Adult",
        "Anaplastic Oligodendroglioma",
        "Anaplastic Astrocytoma",
        "Pilocytic Astrocytoma",
        "Oligodendroglioma",
        "Gliomatosis Cerebri",
        "Pleomorphic Xanthoastrocytoma",
        "Anaplastic Pleomorphic Xanthoastrocytoma",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Ependymoma",
        "Ependymoma, Anaplastic",
        "Medulloblastoma",
        "Teratoid Rhabdoid Tumor",
        "Neuroectodermal Tumors, Primitive",
        "Neuroectodermal Tumors",
        "Anaplastic Meningioma",
        "Atypical Meningioma",
        "Choroid Plexus Neoplasms",
        "Pineal Tumor",
        "Diffuse Astrocytoma",
        "Glial Tumor"
      ],
      "interventions": [
        {
          "name": "ONC206",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2020-10-26",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541082"
    },
    {
      "nct_id": "NCT04771897",
      "title": "A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma",
        "Diffuse Midline Glioma, H3 K27M-Mutant"
      ],
      "interventions": [
        {
          "name": "BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance",
          "type": "DRUG"
        },
        {
          "name": "BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-05-24",
      "completion_date": "2024-10-04",
      "has_results": false,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771897"
    },
    {
      "nct_id": "NCT05835687",
      "title": "Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Central Nervous System Neoplasms",
        "Atypical Teratoid/Rhabdoid Tumor",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Ependymoma",
        "High Grade Glioma",
        "Glioblastoma",
        "Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "B7-H3-CAR T cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-04-27",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-06-10T16:10:34.805Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05835687"
    }
  ]
}